Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf
You may also be interested in...
In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.
Firm plans response to May 1 “approvable” letter that addresses biological activity test criteria, lipid-related impurities.
French drug maker takes control of Tercica, Vernalis’ U.S. subsidiary and Octagen’s investigational hemophilia drug OB-1.